{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:55:07Z","timestamp":1794434107646,"version":"4.9.1"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA016718"],"award-info":[{"award-number":["R01 DA016718"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA035200"],"award-info":[{"award-number":["T32 DA035200"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00213-022-06125-5","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T03:56:47Z","timestamp":1649303807000},"page":"2063-2081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Treatment of opioid overdose: current approaches and recent advances"],"prefix":"10.1007","volume":"239","author":[{"given":"Stevie C.","family":"Britch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"6125_CR1","unstructured":"Abram AK (2017) Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base\/milliliter and 1.0 milligram base\/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. U.S. Food and Drug Administration. https:\/\/www.federalregister.gov\/d\/2017-23952"},{"key":"6125_CR2","unstructured":"Adapt Pharma Operations Limited (2016) FDA advisory committee on the most appropriate dose or doses of naloxone to reverse the effects of fife-threatening opioid overdose in the community settings. https:\/\/www.fda.gov\/media\/100409\/download"},{"key":"6125_CR3","unstructured":"Adapt Pharma Operations Limited (2019) Narcan nasal spray package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208411s001lbl.pdf"},{"key":"6125_CR4","unstructured":"Ahmad FB, Rossen LM, Sutton P (2021) Provisional drug overdose death counts. Center for Disease Control and Prevention, National Center for Health Statistics. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"6125_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/bja\/85.4.533","volume":"85","author":"J Ahonen","year":"2000","unstructured":"Ahonen J, Olkkola KT, Hynynen M, Sepp\u00e4l\u00e4 T, Ik\u00e4valko H, Remmerie B, Salmenper\u00e4 M (2000) Comparison of alfentanil fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. Br J Anaesth 85:533\u2013540. https:\/\/doi.org\/10.1093\/bja\/85.4.533","journal-title":"Br J Anaesth"},{"key":"6125_CR6","unstructured":"Aitken M, Kleinrock M (2019) Medicine use and spending in the U.S. a review of 2018 and outlook to 2023. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023"},{"key":"6125_CR7","unstructured":"Akorn Inc. (2019) Highlights of prescribing information, fentanyl citrate injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/016619s043lbl.pdf"},{"key":"6125_CR8","unstructured":"Altarum (2018) Economic toll of opioid crisis in U.S. exceeded $1 trillion since 2001. Altarum. https:\/\/altarum.org\/news\/economic-toll-opioid-crisis-us-exceeded-1-trillion-2001"},{"key":"6125_CR9","unstructured":"Any Positive Change (2021) Chicago Recovery Alliance Services. https:\/\/anypositivechange.org\/cra-services\/"},{"key":"6125_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.annemergmed.2016.06.014","volume":"69","author":"P Armenian","year":"2017","unstructured":"Armenian P, Olson A, Anaya A, Kurtz A, Ruegner R, Gerona RR (2017) Fentanyl and a novel synthetic opioid U-47700 masquerading as street \u201cnorco\" in central california: A Case Report. Ann Emerg Med 69:87\u201390. https:\/\/doi.org\/10.1016\/j.annemergmed.2016.06.014","journal-title":"Ann Emerg Med"},{"key":"6125_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/03007995.2017.1334637","volume":"34","author":"GK Avetian","year":"2018","unstructured":"Avetian GK, Fiuty P, Mazzella S, Koppa D, Heye V, Hebbar P (2018) Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations. Current medical research and opinion 34:573\u2013576. https:\/\/doi.org\/10.1080\/03007995.2017.1334637","journal-title":"Current medical research and opinion"},{"key":"6125_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/ajhp\/zxz208","volume":"76","author":"R Bardsley","year":"2019","unstructured":"Bardsley R (2019) Higher naloxone dosing may be required for opioid overdose. Am J Health Syst Pharm 76:1835\u20131837. https:\/\/doi.org\/10.1093\/ajhp\/zxz208","journal-title":"Am J Health Syst Pharm"},{"key":"6125_CR13","first-page":"30","volume":"46","author":"F Barrueto Jr","year":"2004","unstructured":"Barrueto F Jr, Howland MA, Hoffman RS, Nelson LS (2004) The Fentanyl Tea Bag Vet Hum Toxicol 46:30\u201331","journal-title":"The Fentanyl Tea Bag Vet Hum Toxicol"},{"key":"6125_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08897077.2018.1449053","volume":"40","author":"A Bell","year":"2019","unstructured":"Bell A, Bennett AS, Jones TS, Doe-Simkins M, Williams LD (2019) Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Subst Abus 40:52\u201355. https:\/\/doi.org\/10.1080\/08897077.2018.1449053","journal-title":"Subst Abus"},{"key":"6125_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/00000542-199711000-00010","volume":"87","author":"JA Bennett","year":"1997","unstructured":"Bennett JA, Abrams JT, Van Riper DF, Horrow JC (1997) Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure. Anesthesiology 87:1070\u20131074. https:\/\/doi.org\/10.1097\/00000542-199711000-00010","journal-title":"Anesthesiology"},{"key":"6125_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1213\/00000539-198212000-00002","volume":"61","author":"JB Bentley","year":"1982","unstructured":"Bentley JB, Borel JD, Nenad RE Jr, Gillespie TJ (1982) Age and Fentanyl Pharmacokinetics. Anesth Analg 61:968\u2013971","journal-title":"Anesth Analg"},{"key":"6125_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.clinthera.2009.02.004","volume":"31","author":"AR Blight","year":"2009","unstructured":"Blight AR, Henney HR 3rd (2009) Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clinical therapeutics 31:328\u2013335. https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.004","journal-title":"Clinical therapeutics"},{"key":"6125_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ajem.2017.02.043","volume":"35","author":"AD Bode","year":"2017","unstructured":"Bode AD, Singh M, Andrews J, Kapur GB, Baez AA (2017) Fentanyl laced heroin and its contribution to a spike in heroin overdose in Miami-Dade County. Am J Emerg Med 35:1364\u20131365. https:\/\/doi.org\/10.1016\/j.ajem.2017.02.043","journal-title":"Am J Emerg Med"},{"key":"6125_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1136\/bmj.298.6689.1713-a","volume":"298","author":"W Burr","year":"1989","unstructured":"Burr W, Sandham P, Judd A (1989) Death after Flumazepil. BMJ 298:1713\u20131713. https:\/\/doi.org\/10.1136\/bmj.298.6689.1713-a","journal-title":"BMJ"},{"key":"6125_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13181-019-00735-w","volume":"16","author":"J Carpenter","year":"2020","unstructured":"Carpenter J, Murray BP, Atti S, Moran TP, Yancey A, Morgan B (2020) Naloxone dosing after opioid overdose in the era of illicitly manufactured fentanyl. J Med Toxicol 16:41\u201348. https:\/\/doi.org\/10.1007\/s13181-019-00735-w","journal-title":"J Med Toxicol"},{"key":"6125_CR21","unstructured":"Center for Drug Evaluation and Research (2015) Approval Package for: Application Number: 208411Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/208411Orig1s000Approv.pdf"},{"key":"6125_CR22","unstructured":"Center for Drug Evaluation and Research (2016) Approval Package for: Application Number: 209862Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209862Orig1s000Approv.pdf"},{"key":"6125_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijoa.2008.10.001","volume":"18","author":"L Coleman","year":"2009","unstructured":"Coleman L, Carvalho B, Lipman S, Schmiesing C, Riley E (2009) Accidental intrathecal sufentanil overdose during combined spinal-epidural analgesia for labor. Int J Obstet Anesth 18:78\u201380. https:\/\/doi.org\/10.1016\/j.ijoa.2008.10.001","journal-title":"Int J Obstet Anesth"},{"key":"6125_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1213\/00000539-198105000-00018","volume":"60","author":"KM Comstock","year":"1981","unstructured":"Comstock KM, Carter GJ, Moyers RJ, Stevens CW (1981) Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia. Anesth Analg 60:362\u2013363. https:\/\/doi.org\/10.1213\/00000539-198105000-00018","journal-title":"Anesth Analg"},{"key":"6125_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1378\/chest.12-2131","volume":"143","author":"B \u00c7oruh","year":"2013","unstructured":"\u00c7oruh B, Tonelli MR, Park DR (2013) Fentanyl-induced chest wall rigidity. Chest 143:1145\u20131146. https:\/\/doi.org\/10.1378\/chest.12-2131","journal-title":"Chest"},{"key":"6125_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bmj.288.6414.363","volume":"288","author":"FM Cuss","year":"1984","unstructured":"Cuss FM, Cola\u00e7o CB, Baron JH (1984) Cardiac arrest after reversal of effects of opiates with naloxone. Br Med J (clin Res Ed) 288:363\u2013364. https:\/\/doi.org\/10.1136\/bmj.288.6414.363","journal-title":"Br Med J (clin Res Ed)"},{"key":"6125_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2019.05.041","volume":"306","author":"B Dhowan","year":"2019","unstructured":"Dhowan B et al (2019) Simple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdose. J Control Release 306:130\u2013137","journal-title":"J Control Release"},{"key":"6125_CR28","doi-asserted-by":"publisher","unstructured":"DiSalvo P, Cooper G, Tsao J, Romeo M, Laskowski LK, Chesney G,\u00a0Su MK (2021) Fentanyl-contaminated cocaine outbreak with laboratory confirmation in New York City in 2019. Am J Emerg Med 40:103\u2013105. https:\/\/doi.org\/10.1016\/j.ajem.2020.12.002","DOI":"10.1016\/j.ajem.2020.12.002"},{"key":"6125_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/j.1552-4604.1987.tb02191.x","volume":"27","author":"R Dixon","year":"1987","unstructured":"Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D (1987) Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 27:233\u2013239. https:\/\/doi.org\/10.1002\/j.1552-4604.1987.tb02191.x","journal-title":"J Clin Pharmacol"},{"key":"6125_CR30","unstructured":"Dunleavy K (2022) Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts. https:\/\/www.fiercepharma.com\/pharma\/teva-and-sandoz-s-generics-have-launched-but-emergent-s-narcan-still-likely-to-thrive"},{"key":"6125_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(73)91879-5","volume":"301","author":"LEJ Evans","year":"1973","unstructured":"Evans LEJ, Swainson CP, Roscoe P, Prescott LF (1973) Treatment of drug overdosage with naloxone a specific narcotic antagonist. The Lancet 301:452\u2013455. https:\/\/doi.org\/10.1016\/S0140-6736(73)91879-5","journal-title":"The Lancet"},{"key":"6125_CR32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ajad.12230","volume":"24","author":"A Fareed","year":"2015","unstructured":"Fareed A, Buchanan-Cummings AM, Crampton K, Grant A, Drexler K (2015) Reversal of overdose on fentanyl being illicitly sold as heroin with naloxone nasal spray: a case report. Am J Addict 24:388\u2013390. https:\/\/doi.org\/10.1111\/ajad.12230","journal-title":"Am J Addict"},{"key":"6125_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000563","author":"GA Fidacaro","year":"2019","unstructured":"Fidacaro GA, Patel P, Carroll G, Bartimus H, Hunter K, Hong R (2019) Do patients require emergency department interventions after prehospital naloxone? J Addict Med. https:\/\/doi.org\/10.1097\/ADM.0000000000000563","journal-title":"J Addict Med"},{"key":"6125_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/bf03005795","volume":"16","author":"FF Foldes","year":"1969","unstructured":"Foldes FF, Duncalf D, Kuwabara S (1969) The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anaesthetized subjects. Can Anaesth Soc J 16:151\u2013161. https:\/\/doi.org\/10.1007\/bf03005795","journal-title":"Can Anaesth Soc J"},{"key":"6125_CR35","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1345\/aph.1L168","volume":"42","author":"D Foster","year":"2008","unstructured":"Foster D, Upton R, Christrup L, Popper L (2008) Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery. Ann Pharmacother 42:1380\u20131387. https:\/\/doi.org\/10.1345\/aph.1L168","journal-title":"Ann Pharmacother"},{"key":"6125_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/cpt.2098","volume":"109","author":"CP France","year":"2021","unstructured":"France CP et al (2021) Countermeasures for preventing and treating opioid overdose. Clin Pharmacol Ther 109:578\u2013590. https:\/\/doi.org\/10.1002\/cpt.2098","journal-title":"Clin Pharmacol Ther"},{"key":"6125_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00000542-198602000-00008","volume":"64","author":"TJ Gal","year":"1986","unstructured":"Gal TJ, Difazio CA (1986) Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology 64:175\u2013180. https:\/\/doi.org\/10.1097\/00000542-198602000-00008","journal-title":"Anesthesiology"},{"key":"6125_CR38","doi-asserted-by":"publisher","first-page":"A344","DOI":"10.1097\/00000542-198609001-00342","volume":"65","author":"TJ Gal","year":"1986","unstructured":"Gal TJ, Difazio CA, Dixon R (1986) Prolonged blockage of opioid effects with oral nalmefene. Anesthesiology 65:A344. https:\/\/doi.org\/10.1097\/00000542-198609001-00342","journal-title":"Anesthesiology"},{"key":"6125_CR39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1213\/00000539-199403000-00021","volume":"78","author":"SAP Glass","year":"1994","unstructured":"Glass SAP, Jhaveri MR, Smith RL (1994) Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg 78:536\u2013541. https:\/\/doi.org\/10.1213\/00000539-199403000-00021","journal-title":"Anesth Analg"},{"key":"6125_CR40","unstructured":"Global Newswire (2021) Adamis received FDA approval for ZIMHI. https:\/\/www.globenewswire.com\/en\/news-release\/2021\/10\/18\/2315581\/32832\/en\/Adamis-Receives-FDA-Approval-for-ZIMHI.html"},{"key":"6125_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1213\/00000539-197007000-00003","volume":"49","author":"LF Grell","year":"1970","unstructured":"Grell LF, Koons AR, Denson SJ (1970) Fentanyl in anesthesia: A Report of 500 Cases. Anesth Analg 49:523\u2013532. https:\/\/doi.org\/10.1213\/00000539-197007000-00003","journal-title":"Anesth Analg"},{"key":"6125_CR42","unstructured":"Hargan ED (2017) Determination that a public health Emergency Exists. https:\/\/www.phe.gov\/emergency\/news\/healthactions\/phe\/Pages\/opioids.aspx"},{"key":"6125_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0091270003251388","volume":"43","author":"KC Hayes","year":"2003","unstructured":"Hayes KC, Katz MA, Devane JG, Hsieh JT, Wolfe DL, Potter PJ, Blight AR (2003) Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 43:379\u2013385. https:\/\/doi.org\/10.1177\/0091270003251388","journal-title":"J Clin Pharmacol"},{"key":"6125_CR44","unstructured":"Hedegaard H, Minino AM, Warner M (2020) Drug overdose deaths in the United States, 1999-2018. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db356_tables-508.pdf#page=3"},{"key":"6125_CR45","unstructured":"Hikma Specialty USA Inc. (2021) Highlights of prescribing information, Kloxxado. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212045s000lbl.pdf"},{"key":"6125_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/00000542-198110000-00021","volume":"55","author":"BA Hill","year":"1981","unstructured":"Hill BA, Nahrwold LM, De Rosayro MA, Knight RP, Jones MR, Bolles ER (1981) Prevention of rigidity during fentanyl\u2013oxygen induction of anesthesia. Anesthesiology 55:452\u2013454. https:\/\/doi.org\/10.1097\/00000542-198110000-00021","journal-title":"Anesthesiology"},{"key":"6125_CR47","doi-asserted-by":"publisher","first-page":"103457","DOI":"10.1016\/j.drugpo.2021.103457","volume":"99","author":"LG Hill","year":"2022","unstructured":"Hill LG, Zagorski CM, Loera LJ (2022) Increasingly powerful opioid antagonists are not necessary. Int J Drug Policy 99:103457. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103457","journal-title":"Int J Drug Policy"},{"key":"6125_CR48","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcfm.2005.01.011","volume":"12","author":"R Hunter","year":"2005","unstructured":"Hunter R (2005) Ventricular tachycardia following naloxone administration in an illicit drug misuse. J Clin Forensic Med 12:218\u2013219. https:\/\/doi.org\/10.1016\/j.jcfm.2005.01.011","journal-title":"J Clin Forensic Med"},{"key":"6125_CR49","doi-asserted-by":"publisher","unstructured":"Imam M, Kuo A, Smith M (2020) Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants [version 1; peer review: 2 approved] F1000Research 9 https:\/\/doi.org\/10.12688\/f1000research.21738.1","DOI":"10.12688\/f1000research.21738.1"},{"key":"6125_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1756285613512712","volume":"7","author":"HB Jensen","year":"2014","unstructured":"Jensen HB, Ravnborg M, Dalgas U, Stenager E (2014) 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord 7:97\u2013113. https:\/\/doi.org\/10.1177\/1756285613512712","journal-title":"Ther Adv Neurol Disord"},{"key":"6125_CR51","doi-asserted-by":"publisher","first-page":"e0183821","DOI":"10.1371\/journal.pone.0183821","volume":"12","author":"KGV Johansen","year":"2017","unstructured":"Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R (2017) Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials. PloS One 12:e0183821. https:\/\/doi.org\/10.1371\/journal.pone.0183821","journal-title":"PloS One"},{"key":"6125_CR52","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bja.2018.02.021","volume":"120","author":"K Jonkman","year":"2018","unstructured":"Jonkman K et al (2018) Esketamine counters opioid-induced respiratory depression. Br J Anaesth 120:1117\u20131127. https:\/\/doi.org\/10.1016\/j.bja.2018.02.021","journal-title":"Br J Anaesth"},{"key":"6125_CR53","unstructured":"Kaleo Inc. (2014) Highlights of prescribing information, EVZIO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205787orig1s000lbl.pdf"},{"key":"6125_CR54","unstructured":"Kaleo Inc. (2016) Highlights of prescribing information, EVZIO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209862lbl.pdf"},{"key":"6125_CR55","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-151919\/v1","author":"K Kanter","year":"2021","unstructured":"Kanter K et al (2021) Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in philadelphia. Harm Reduct J. https:\/\/doi.org\/10.21203\/rs.3.rs-151919\/v1","journal-title":"Harm Reduct J"},{"key":"6125_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0196-0644(99)70270-2","volume":"34","author":"JL Kaplan","year":"1999","unstructured":"Kaplan JL et al (1999) Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emergency Med 34:42\u201350","journal-title":"Ann Emergency Med"},{"key":"6125_CR57","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1097\/00000542-198009001-00095","volume":"53","author":"ML Kentor","year":"1980","unstructured":"Kentor ML, Schwalb AJ, Lieberman RW (1980) Rapid high dose fentanyl induction for CABG. Anesthesiology 53:S95","journal-title":"Anesthesiology"},{"key":"6125_CR58","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/j.1360-0443.2009.02724.x","volume":"104","author":"D Kerr","year":"2009","unstructured":"Kerr D, Kelly AM, Dietze P, Jolley D, Barger B (2009) Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 104:2067\u20132074. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02724.x","journal-title":"Addiction"},{"key":"6125_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14740338.2019.1613372","volume":"18","author":"HK Kim","year":"2019","unstructured":"Kim HK, Connors NJ, Mazer-Amirshahi ME (2019) The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin Drug Saf 18:465\u2013475. https:\/\/doi.org\/10.1080\/14740338.2019.1613372","journal-title":"Expert Opin Drug Saf"},{"key":"6125_CR60","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/10903127.2015.1076097","volume":"20","author":"BB Kitch","year":"2016","unstructured":"Kitch BB, Portela RC (2016) Effective use of naloxone by law enforcement in response to multiple opioid overdoses. Prehosp Emerg Care 20:226\u2013229. https:\/\/doi.org\/10.3109\/10903127.2015.1076097","journal-title":"Prehosp Emerg Care"},{"key":"6125_CR61","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/bja\/61.3.318","volume":"61","author":"KM Konieczko","year":"1988","unstructured":"Konieczko KM, Jones JG, Barrowcliffe MP, Jordan C, Altman DG (1988) Antagonism of morphine-induced respiratory depression with nalmefene. Br J Anaesth 61:318\u2013323. https:\/\/doi.org\/10.1093\/bja\/61.3.318","journal-title":"Br J Anaesth"},{"key":"6125_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1124\/jpet.118.256115","volume":"371","author":"P Krieter","year":"2019","unstructured":"Krieter P, Gyaw S, Crystal R, Skolnick P (2019) Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther 371:409\u2013415. https:\/\/doi.org\/10.1124\/jpet.118.256115","journal-title":"J Pharmacol Exp Ther"},{"key":"6125_CR63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s40800-014-0002-0","volume":"1","author":"H Lameijer","year":"2014","unstructured":"Lameijer H, Azizi N, Ligtenberg JJM, Ter Maaten JC (2014) Ventricular tachycardia after naloxone administration: a Drug Related Complication? Case Report and Literature Review Drug Saf Case Rep 1:2\u20132. https:\/\/doi.org\/10.1007\/s40800-014-0002-0","journal-title":"Case Report and Literature Review Drug Saf Case Rep"},{"key":"6125_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/adm.0000000000000045","volume":"8","author":"MR Lofwall","year":"2014","unstructured":"Lofwall MR, Walsh SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 8:315\u2013326. https:\/\/doi.org\/10.1097\/adm.0000000000000045","journal-title":"J Addict Med"},{"key":"6125_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-3956(92)90014-f","volume":"26","author":"N Loimer","year":"1992","unstructured":"Loimer N, Hofmann P, Chaudhry HR (1992) Nasal administration of naloxone for detection of opiate dependence. J Psychiatr Res 26:39\u201343. https:\/\/doi.org\/10.1016\/0022-3956(92)90014-f","journal-title":"J Psychiatr Res"},{"key":"6125_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0304-3940(93)90723-x","volume":"157","author":"PW Lui","year":"1993","unstructured":"Lui PW, Chang GJ, Lee TY, Chan SH (1993) Antagonization of fentanyl-induced muscular rigidity by denervation of the coerulospinal noradrenergic pathway in the rat. Neurosci Lett 157:145\u2013148. https:\/\/doi.org\/10.1016\/0304-3940(93)90723-x","journal-title":"Neurosci Lett"},{"key":"6125_CR67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0304-3940(89)90252-8","volume":"96","author":"PW Lui","year":"1989","unstructured":"Lui PW, Lee TY, Chan SH (1989) Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Neurosci Lett 96:114\u2013119. https:\/\/doi.org\/10.1016\/0304-3940(89)90252-8","journal-title":"Neurosci Lett"},{"key":"6125_CR68","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0304-3940(90)90728-r","volume":"108","author":"PW Lui","year":"1990","unstructured":"Lui PW, Lee TY, Chan SH (1990) Involvement of coerulospinal noradrenergic pathway in fentanyl-induced muscular rigidity in rats. Neurosci Lett 108:183\u2013188. https:\/\/doi.org\/10.1016\/0304-3940(90)90728-r","journal-title":"Neurosci Lett"},{"key":"6125_CR69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0304-3940(95)12162-5","volume":"201","author":"PW Lui","year":"1995","unstructured":"Lui PW, Tsen LY, Fu MJ, Yeh CP, Lee TY, Chan SH (1995) Inhibition by intrathecal prazosin but not yohimbine of fentanyl-induced muscular rigidity in the rat. Neurosci Lett 201:167\u2013170. https:\/\/doi.org\/10.1016\/0304-3940(95)12162-5","journal-title":"Neurosci Lett"},{"key":"6125_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2042098617744161","volume":"9","author":"RR Lynn","year":"2018","unstructured":"Lynn RR, Galinkin J (2018) Naloxone Dosage for Opioid Reversal: Current Evidence and Clinical Implications. Ther Adv Drug Safe 9:63\u201388. https:\/\/doi.org\/10.1177\/2042098617744161","journal-title":"Ther Adv Drug Safe"},{"key":"6125_CR71","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/PEC.0b013e31825358b4","volume":"28","author":"MD Lyttle","year":"2012","unstructured":"Lyttle MD, Verma S, Isaac R (2012) Transdermal fentanyl in deliberate overdose in pediatrics. Pediatr Emerg Care 28:463\u2013464. https:\/\/doi.org\/10.1097\/PEC.0b013e31825358b4","journal-title":"Pediatr Emerg Care"},{"key":"6125_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/15563650.2019.1615622","volume":"58","author":"SG Mahonski","year":"2020","unstructured":"Mahonski SG, Leonard JB, Gatz JD, Seung H, Haas EE, Kim HK (2020) Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data. Clin Toxicol (phila) 58:117\u2013123. https:\/\/doi.org\/10.1080\/15563650.2019.1615622","journal-title":"Clin Toxicol (phila)"},{"key":"6125_CR73","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jemermed.2018.04.022","volume":"55","author":"CA Marco","year":"2018","unstructured":"Marco CA, Trautman W, Cook A, Mann D, Rasp J, Perkins O, Ballester M (2018) Naloxone use among emergency department patients with opioid overdose. J Emerg Med 55:64\u201370. https:\/\/doi.org\/10.1016\/j.jemermed.2018.04.022","journal-title":"J Emerg Med"},{"key":"6125_CR74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/15563659409000433","volume":"32","author":"KA Marquardt","year":"1994","unstructured":"Marquardt KA, Tharratt RS (1994) Inhalation abuse of fentanyl patch. J Toxicol Clin Toxicol 32:75\u201378. https:\/\/doi.org\/10.3109\/15563659409000433","journal-title":"J Toxicol Clin Toxicol"},{"key":"6125_CR75","doi-asserted-by":"publisher","unstructured":"Massey J et al (2017) Opioid overdose outbreak - West Virginia, August 2016. MMWR Morb Mortal Wkly Rep 66:975\u2013980. https:\/\/doi.org\/10.15585\/mmwr.mm6637a3","DOI":"10.15585\/mmwr.mm6637a3"},{"key":"6125_CR76","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/add.14033","volume":"113","author":"R McDonald","year":"2018","unstructured":"McDonald R et al (2018) Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction 113:484\u2013493. https:\/\/doi.org\/10.1111\/add.14033","journal-title":"Addiction"},{"key":"6125_CR77","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13054-020-2835-5","volume":"24","author":"B M\u00e9garbane","year":"2020","unstructured":"M\u00e9garbane B, Chevillard L, Vodovar D (2020) Naloxone should remain the appropriate antidote to treat opioid overdose. Crit Care 24:173. https:\/\/doi.org\/10.1186\/s13054-020-2835-5","journal-title":"Crit Care"},{"key":"6125_CR78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0735-6757(93)90074-l","volume":"11","author":"KS Merigian","year":"1993","unstructured":"Merigian KS (1993) Cocaine-induced ventricular arrhythmias and rapid atrial fibrillation temporally related to naloxone administration. Am J Emerg Med 11:96\u201397. https:\/\/doi.org\/10.1016\/0735-6757(93)90074-l","journal-title":"Am J Emerg Med"},{"key":"6125_CR79","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/10903127.2017.1335818","volume":"21","author":"MA Merlin","year":"2017","unstructured":"Merlin MA et al (2017) Incidence of naloxone redosing in the age of the new opioid epidemic. Prehosp Emerg Care 21:682\u2013687. https:\/\/doi.org\/10.1080\/10903127.2017.1335818","journal-title":"Prehosp Emerg Care"},{"key":"6125_CR80","doi-asserted-by":"publisher","first-page":"108974","DOI":"10.1016\/j.drugalcdep.2021.108974","volume":"227","author":"NB Miner","year":"2021","unstructured":"Miner NB, Schutzer WE, Zarnegarnia Y, Janowsky A, Torralva R (2021) Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments. Drug Alcohol Depend 227:108974. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108974","journal-title":"Drug Alcohol Depend"},{"key":"6125_CR81","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/0019-5359.49240","volume":"63","author":"SS Nath","year":"2009","unstructured":"Nath SS, Tripathi M, Pandey C, Rao B (2009) Naloxone-induced pulmonary edema: a potential cause of postoperative morbidity in laparoscopic donor nephrectomy. Indian J Med Sci 63:72\u201375. https:\/\/doi.org\/10.4103\/0019-5359.49240","journal-title":"Indian J Med Sci"},{"key":"6125_CR82","unstructured":"National Institute on Drug Abuse (2021) Trends and statistics in overdose death rates. https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates"},{"key":"6125_CR83","unstructured":"National Library of Medicine (2021a) PubChem compound summary for CID 3345, fentanyl. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Fentanyl"},{"key":"6125_CR84","unstructured":"National Library of Medicine (2021b) PubChem compound summary for CID 5284596, naloxone. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Naloxone"},{"key":"6125_CR85","unstructured":"National Library of Medicine (2021c) PubChem compound summary for CID 5288826, morphine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5288826"},{"key":"6125_CR86","doi-asserted-by":"publisher","unstructured":"Nielsen S et al (2020) Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018. Addiction 115:1075\u20131087. https:\/\/doi.org\/10.1111\/add.14896","DOI":"10.1111\/add.14896"},{"key":"6125_CR87","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J (2021) Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls \u2014 United States, 2019\u20132020. https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7050e3.htm?s_cid=mm7050e3_w#suggestedcitation","DOI":"10.15585\/mmwr.mm7050e3"},{"key":"6125_CR88","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/clpt.2009.194","volume":"87","author":"BG Oertel","year":"2010","unstructured":"Oertel BG et al (2010) Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia. Clin Pharmacol Ther 87:204\u2013211. https:\/\/doi.org\/10.1038\/clpt.2009.194","journal-title":"Clin Pharmacol Ther"},{"key":"6125_CR89","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1097\/ALN.0b013e3181d5e29d","volume":"112","author":"E Olofsen","year":"2010","unstructured":"Olofsen E, Van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, Sarton E (2010) Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic\u2013pharmacodynamic modeling study. Anesthesiology 112:1417\u20131427. https:\/\/doi.org\/10.1097\/ALN.0b013e3181d5e29d","journal-title":"Anesthesiology"},{"key":"6125_CR90","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/15563659609013811","volume":"34","author":"JJ Osterwalder","year":"1996","unstructured":"Osterwalder JJ (1996) Naloxone\u2013for intoxications with intravenous heroin and heroin mixtures\u2013harmless or hazardous? A Prospect Clin Study J Toxicol Clin Toxicol 34:409\u2013416. https:\/\/doi.org\/10.3109\/15563659609013811","journal-title":"A Prospect Clin Study J Toxicol Clin Toxicol"},{"key":"6125_CR91","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11524-019-00365-1","volume":"96","author":"J Park","year":"2019","unstructured":"Park J et al (2019) Willingness to use safe consumption spaces among opioid users at high risk of fentanyl overdose in Baltimore Providence, and Boston. J Urban Health 96:353\u2013366. https:\/\/doi.org\/10.1007\/s11524-019-00365-1","journal-title":"J Urban Health"},{"key":"6125_CR92","unstructured":"Paulozzi LJ, Jones CM, Mack KA, Rudd RA (2011) Vital signs: overdoses of prescription opioid pain relievers\u2014United States, 1999\u20132008. MMWR MorbMortal Wkly Rep. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6043a4.htm"},{"key":"6125_CR93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bcpt.12434","volume":"118","author":"EI Penninga","year":"2016","unstructured":"Penninga EI, Graudal N, Ladekarl MB, J\u00fcrgens G (2016) Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication\u2014a systematic review with meta-analyses of randomised trials Basic. Clin Pharmacol Toxicol 118:37\u201344. https:\/\/doi.org\/10.1111\/bcpt.12434","journal-title":"Clin Pharmacol Toxicol"},{"key":"6125_CR94","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/jcpt.13484","volume":"46","author":"JV Pergolizzi Jr","year":"2021","unstructured":"Pergolizzi JV Jr, Webster LR, Vortsman E, Ann LeQuang J, Raffa RB (2021) Wooden chest syndrome: The Atypical Pharmacology of Fentanyl Overdose. J Clin Pharm Ther 46:1505\u20131508. https:\/\/doi.org\/10.1111\/jcpt.13484","journal-title":"J Clin Pharm Ther"},{"key":"6125_CR95","unstructured":"Prescriber\u2019s Digital Reference (2021) fentanyl - Drug Summary. https:\/\/www.pdr.net\/drug-summary\/Fentora-fentanyl-2330"},{"key":"6125_CR96","unstructured":"PRNewswire (2021) Sandoz launches authorized generic of Narcan\u00ae (naloxone hydrochloride) Nasal Spray 4 mg in US to help reverse opioid overdose, expanding access during surge in overdose deaths. https:\/\/www.prnewswire.com\/news-releases\/sandoz-launches-authorized-generic-of-narcan-naloxone-hydrochloride-nasal-spray-4-mg-in-us-to-help-reverse-opioid-overdose-expanding-access-during-surge-in-overdose-deaths-301450103.html"},{"key":"6125_CR97","unstructured":"Purdue Pharma (2019) FDA grants competitive generic therapy (CGT) designation to Purdue Pharma\u2019s investigational nalmefene HCl injection for the emergency treatment of known or suspected opioid overdose. https:\/\/purduepharma.com\/news\/2019\/04\/24\/fda-grants-competitive-generic-therapy-cgt-designation-to-purdue-pharmas-investigational-nalmefene-hcl-injection-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose\/"},{"key":"6125_CR98","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15563650.2020.1758325","volume":"59","author":"R Purssell","year":"2021","unstructured":"Purssell R et al (2021) Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. Clin Toxicol 59:38\u201346. https:\/\/doi.org\/10.1080\/15563650.2020.1758325","journal-title":"Clin Toxicol"},{"key":"6125_CR99","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5055\/jom.2019.0531","volume":"15","author":"A Raheemullah","year":"2019","unstructured":"Raheemullah A, Andruska N (2019) Fentanyl analogue overdose: Key Lessons in Management in the Synthetic Apioid Age. J Opioid Manag 15:428\u2013432. https:\/\/doi.org\/10.5055\/jom.2019.0531","journal-title":"J Opioid Manag"},{"key":"6125_CR100","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1056\/NEJMcpc1710563","volume":"377","author":"AS Raja","year":"2017","unstructured":"Raja AS, Miller ES, Flores EJ, Wakeman SE, Eng G (2017) Case 37\u20132017. A 36-year-old man with unintentional opioid overdose. N Engl J Med 377:2181\u20132188. https:\/\/doi.org\/10.1056\/NEJMcpc1710563","journal-title":"N Engl J Med"},{"key":"6125_CR101","unstructured":"RespireRX Pharmaceuticals Inc. (2016) RespireRx Pharmaceuticals Inc. announces data for CX1739 clinical study in opioid induced respiratory depression. http:\/\/respirerx.com\/respirerx-pharmaceuticals-inc-announces-data-for-cx1739-clinical-study-in-opioid-induced-respiratory-depression\/"},{"key":"6125_CR102","unstructured":"Rhyan CN (2017) The potential societal benefit of eliminating opioid overdoses, deaths, and substance use disorders exceeds $95 billion per year. https:\/\/altarum.org\/sites\/default\/files\/uploaded-publication-files\/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf"},{"key":"6125_CR103","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jemermed.2015.10.014","volume":"50","author":"JS Rogers","year":"2016","unstructured":"Rogers JS, Rehrer SJ, Hoot NR (2016) Acetylfentanyl: An Emerging Drug of Abuse. J Emerg Med 50:433\u2013436. https:\/\/doi.org\/10.1016\/j.jemermed.2015.10.014","journal-title":"J Emerg Med"},{"key":"6125_CR104","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cpt.601","volume":"102","author":"M Roozekrans","year":"2017","unstructured":"Roozekrans M, Olofsen E, van der Schrier R, Boom M, Mooren R, Dahan A (2017) Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic\/Pharmacodynamic-Pharmacokinetic\/Pharmacodynamic Modeling Study in Healthy Volunteers. Clin Pharmacol Ther 102:115\u2013122. https:\/\/doi.org\/10.1002\/cpt.601","journal-title":"Clin Pharmacol Ther"},{"key":"6125_CR105","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/cpt.99","volume":"97","author":"M Roozekrans","year":"2015","unstructured":"Roozekrans M, Olofsen E, van der Schrier R, van Gerven J, Peng S, McLeod J, Dahan A (2015) Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Clin Pharmacol Ther 97:641\u2013649. https:\/\/doi.org\/10.1002\/cpt.99","journal-title":"Clin Pharmacol Ther"},{"key":"6125_CR106","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/aln.0000000000000367","volume":"121","author":"M Roozekrans","year":"2014","unstructured":"Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A (2014) Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology 121:459\u2013468. https:\/\/doi.org\/10.1097\/aln.0000000000000367","journal-title":"Anesthesiology"},{"key":"6125_CR107","doi-asserted-by":"publisher","unstructured":"Rowe C, Wheeler E, Stephen Jones T, Yeh C, Coffin PO (2019) Community-based response to fentanyl overdose outbreak, San Francisco, 2015. J Urban Health 96:6\u201311. https:\/\/doi.org\/10.1007\/s11524-018-0250-x","DOI":"10.1007\/s11524-018-0250-x"},{"key":"6125_CR108","unstructured":"Rudd RA et al. (2014) Increases in heroin overdose deaths\u201428 states, 2010 to 2012. MMWR MorbMortal Wkly Rep. Center for Disease Control and Prevention. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6339a1.htm"},{"key":"6125_CR109","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1365-2044.1989.tb09119.x","volume":"44","author":"JP Ryan","year":"1989","unstructured":"Ryan JP, Meakin G (1989) Fentanyl overdose in a neonate: use of naloxone infusion. Anaesthesia 44:864\u2013865. https:\/\/doi.org\/10.1111\/j.1365-2044.1989.tb09119.x","journal-title":"Anaesthesia"},{"key":"6125_CR110","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/pmt-2017-0060","volume":"8","author":"SA Ryan","year":"2018","unstructured":"Ryan SA, Dunne RB (2018) Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain Management 8:231\u2013245. https:\/\/doi.org\/10.2217\/pmt-2017-0060","journal-title":"Pain Management"},{"key":"6125_CR111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.annemergmed.2018.10.024","volume":"73","author":"C Santos","year":"2019","unstructured":"Santos C, Adam A, Calello D, Nelson L (2019) Safety of a brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann Emerg Med 73:99\u2013100. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.10.024","journal-title":"Ann Emerg Med"},{"key":"6125_CR112","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1213\/00000539-198303000-00008","volume":"62","author":"FL Scamman","year":"1983","unstructured":"Scamman FL (1983) Fentanyl-O2-N2O rigidity and pulmonary compliance. Anesth Analg 62:332\u2013334","journal-title":"Anesth Analg"},{"key":"6125_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annemergmed.2018.01.054","volume":"72","author":"FX Scheuermeyer","year":"2018","unstructured":"Scheuermeyer FX et al (2018) Safety of a brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann Emerg Med 72:1-8.e1. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.01.054","journal-title":"Ann Emerg Med"},{"key":"6125_CR114","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/15563650701877374","volume":"46","author":"H Schumann","year":"2008","unstructured":"Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JS (2008) Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol 46:501\u2013506. https:\/\/doi.org\/10.1080\/15563650701877374","journal-title":"Clin Toxicol"},{"key":"6125_CR115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/bja\/53.4.373","volume":"53","author":"RL Sia","year":"1981","unstructured":"Sia RL, Zandstra DF (1981) 4-Aminopyridine reversal of fentanyl-induced respiratory depression in normocapnic and hypercapnic patients. Br J Anaesth 53:373\u2013379. https:\/\/doi.org\/10.1093\/bja\/53.4.373","journal-title":"Br J Anaesth"},{"key":"6125_CR116","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1177\/0009922819877870","volume":"58","author":"B Slingsby","year":"2019","unstructured":"Slingsby B, Moore JL, Barron CE (2019) Infant and toddler ingestion of illicit fentanyl: a case series. Clin Pediatr (phila) 58:1449\u20131451. https:\/\/doi.org\/10.1177\/0009922819877870","journal-title":"Clin Pediatr (phila)"},{"key":"6125_CR117","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5414\/cp201646","volume":"50","author":"K Smith","year":"2012","unstructured":"Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Bell D (2012) Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 50:360\u2013367. https:\/\/doi.org\/10.5414\/cp201646","journal-title":"Int J Clin Pharmacol Ther"},{"key":"6125_CR118","doi-asserted-by":"publisher","unstructured":"Somerville NJ et al. (2017) Characteristics of fentanyl overdose \u2014 Massachusetts, 2014\u20132016 Morbidity and Mortality Weekly Report 66:382\u2013386 https:\/\/doi.org\/10.15585\/mmwr.mm6614a2","DOI":"10.15585\/mmwr.mm6614a2"},{"key":"6125_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00540-003-0214-4","volume":"18","author":"M Takahashi","year":"2004","unstructured":"Takahashi M, Sugiyama K, Hori M, Chiba S, Kusaka K (2004) Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl. J Anesth 18:1\u20138. https:\/\/doi.org\/10.1007\/s00540-003-0214-4","journal-title":"J Anesth"},{"key":"6125_CR120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0022-3565(25)11509-7","volume":"113","author":"DV Thomas","year":"1955","unstructured":"Thomas DV, Tenney SM (1955) The effect of levorphan and levallorphan on the respiratory mechanism of normal man. J Pharmacol Exp Ther 113:250\u2013255","journal-title":"J Pharmacol Exp Ther"},{"key":"6125_CR121","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1399-6576.1977.tb01248.x","volume":"21","author":"I Tigerstedt","year":"1977","unstructured":"Tigerstedt I (1977) Antagonism of fentanyl with naloxone during N2O+O2+ halothane anaesthesia Acta anaesthesiologica. Scandinavica 21:470\u2013480. https:\/\/doi.org\/10.1111\/j.1399-6576.1977.tb01248.x","journal-title":"Scandinavica"},{"key":"6125_CR122","doi-asserted-by":"publisher","unstructured":"Tomassoni AJ et al (2017) Multiple fentanyl overdoses - New Haven, Connecticut, June 23 2016. MMWR Morb Mortal Wkly Rep 66:107\u2013111. https:\/\/doi.org\/10.15585\/mm6604a4","DOI":"10.15585\/mm6604a4"},{"key":"6125_CR123","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1124\/jpet.119.258566","volume":"371","author":"R Torralva","year":"2019","unstructured":"Torralva R, Janowsky A (2019) Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. J Pharmacol Exp Ther 371:453\u2013475. https:\/\/doi.org\/10.1124\/jpet.119.258566","journal-title":"J Pharmacol Exp Ther"},{"key":"6125_CR124","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00228-016-2191-1","volume":"73","author":"I Tylleskar","year":"2017","unstructured":"Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O (2017) Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol 73:555\u2013562","journal-title":"Eur J Clin Pharmacol"},{"key":"6125_CR125","unstructured":"U.S. Food & Drug Administration (2019) FDA approves first generic naloxone nasal spray to treat opioid overdose. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-naloxone-nasal-spray-treat-opioid-overdose"},{"key":"6125_CR126","unstructured":"U.S. Food and Drug Administration NDA 016636. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016636"},{"key":"6125_CR127","unstructured":"U.S. Food and Drug Administration (2021a) FDA approves higher dosage of naloxone nasal spray to treat opioid overdose. FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-higher-dosage-naloxone-nasal-spray-treat-opioid-overdose"},{"key":"6125_CR128","unstructured":"U.S. Food and Drug Administration (2021b) FDA approves naloxone injection to counteract opioid overdoses. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-naloxone-injection-counteract-opioid-overdoses"},{"key":"6125_CR129","unstructured":"U.S. Food and Drug Administration (2021c) Orange book: Approved Drug Products with Therapeutic Equivalence Evaluations. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/results_product.cfm?Appl_Type=N&Appl_No=209862#17222"},{"key":"6125_CR130","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000542-200607000-00012","volume":"105","author":"E van Dorp","year":"2006","unstructured":"van Dorp E et al (2006) Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 105:51\u201357. https:\/\/doi.org\/10.1097\/00000542-200607000-00012","journal-title":"Anesthesiology"},{"key":"6125_CR131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/wps.20846","volume":"20","author":"ND Volkow","year":"2021","unstructured":"Volkow ND (2021) The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry 20:195\u2013196. https:\/\/doi.org\/10.1002\/wps.20846","journal-title":"World Psychiatry"},{"key":"6125_CR132","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow ND, Collins FS (2017) The role of science in addressing the opioid crisis. N Engl J Med 377:391\u2013394. https:\/\/doi.org\/10.1056\/NEJMsr1706626","journal-title":"N Engl J Med"},{"key":"6125_CR133","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/15563650.2021.1882682","volume":"59","author":"G Wahl","year":"2021","unstructured":"Wahl G, Gault A (2021) Reversal of Ingested Fentanyl Patch Toxicity with Oral Naltrexone in Remote Australia: Case Report. Clin Toxicol (phila) 59:854\u2013855. https:\/\/doi.org\/10.1080\/15563650.2021.1882682","journal-title":"Clin Toxicol (phila)"},{"key":"6125_CR134","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0091-3057(88)90022-6","volume":"29","author":"MB Weinger","year":"1988","unstructured":"Weinger MB, Cline EJ, Smith NT, Blasco TA, Koob GF (1988) Localization of brainstem sites which mediate alfentanil-induced muscle rigidity in the rat. Pharmacol Biochem Behav 29:573\u2013580. https:\/\/doi.org\/10.1016\/0091-3057(88)90022-6","journal-title":"Pharmacol Biochem Behav"},{"key":"6125_CR135","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/j.1360-0443.2008.02244.x","volume":"103","author":"C Welsh","year":"2008","unstructured":"Welsh C, Sherman SG, Tobin KE (2008) A case of heroin overdose reversed by sublingually administered buprenorphine\/naloxone (Suboxone). Addiction 103:1226\u20131228. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02244.x","journal-title":"Addiction"},{"key":"6125_CR136","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0022-3565(25)05224-3","volume":"109","author":"A Wikler","year":"1953","unstructured":"Wikler A, Fraser HF, Isbell H (1953) N-Allylnormorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine; methadone or heroin in man (post addicts). J Pharmacol Exp Ther 109:8\u201320","journal-title":"J Pharmacol Exp Ther"},{"key":"6125_CR137","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.toxlet.2019.11.025","volume":"320","author":"M Wilde","year":"2020","unstructured":"Wilde M, Sommer MJ, Auw\u00e4rter V, Hermanns-Clausen M (2020) Acute severe intoxication with cyclopropylfentanyl, a novel synthetic opioid. Toxicol Lett 320:109\u2013112. https:\/\/doi.org\/10.1016\/j.toxlet.2019.11.025","journal-title":"Toxicol Lett"},{"key":"6125_CR138","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5055\/jom.2012.0098","volume":"8","author":"MA Yokell","year":"2012","unstructured":"Yokell MA, Zaller ND, Green TC, McKenzie M, Rich JD (2012) Intravenous use of illicit buprenorphine\/naloxone to reverse an acute heroin overdose. J Opioid Manag 8:63\u201366. https:\/\/doi.org\/10.5055\/jom.2012.0098","journal-title":"J Opioid Manag"},{"key":"6125_CR139","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13054-020-2740-y","volume":"24","author":"N Zamani","year":"2020","unstructured":"Zamani N, Buckley NA, Hassanian-Moghaddam H (2020) Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Crit Care 24:44. https:\/\/doi.org\/10.1186\/s13054-020-2740-y","journal-title":"Crit Care"},{"key":"6125_CR140","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.annemergmed.2016.12.024","volume":"69","author":"N Zamani","year":"2017","unstructured":"Zamani N, Hassanian-Moghaddam H (2017) Intravenous buprenorphine: a substitute for naloxone in methadone-overdosed patients? Ann Emerg Med 69:737\u2013739. https:\/\/doi.org\/10.1016\/j.annemergmed.2016.12.024","journal-title":"Ann Emerg Med"},{"key":"6125_CR141","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3109\/10903127.2014.896961","volume":"18","author":"M Zuckerman","year":"2014","unstructured":"Zuckerman M, Weisberg SN, Boyer EW (2014) Pitfalls of Intranasal Naloxone. Prehosp Emerg Care 18:550\u2013554. https:\/\/doi.org\/10.3109\/10903127.2014.896961","journal-title":"Prehosp Emerg Care"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06125-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:27:24Z","timestamp":1744198044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06125-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":141,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6125"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06125-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"25 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sharon Walsh serves on a Scientific Advisory Board for Opiant Pharmaceuticals and as an advisor for Pocket Naloxone.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}